Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Receivables: 2020-2022

  • Fulcrum Therapeutics' Receivables was N/A to $803,000 in Q3 2022 from the same period last year, while for Sep 2022 it was $8.1 million, marking a year-over-year change of. This contributed to the annual value of $3.6 million for FY2021, which is 43.70% up from last year.
  • According to the latest figures from Q3 2022, Fulcrum Therapeutics' Receivables is $803,000, which was down 27.00% from $1.1 million recorded in Q2 2022.
  • Fulcrum Therapeutics' 5-year Receivables high stood at $3.6 million for Q4 2021, and its period low was $803,000 during Q3 2022.
  • Moreover, its 3-year median value for Receivables was $1.8 million (2020), whereas its average is $2.0 million.
  • Data for Fulcrum Therapeutics' Receivables shows a peak YoY soared of 43.70% (in 2021) over the last 5 years.
  • Over the past 3 years, Fulcrum Therapeutics' Receivables (Quarterly) stood at $2.5 million in 2020, then spiked by 43.70% to $3.6 million in 2021, then reached $803,000 in 2022.
  • Its Receivables stands at $803,000 for Q3 2022, versus $1.1 million for Q2 2022 and $3.6 million for Q4 2021.